Similar articles

• Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.

  Francoz S, Froment P, Bogaerts S, De Clercq S, Maetens M, Doumont G, Bellefroid E, Marine JC. Francoz S, et al. Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3232-7. doi: 10.1073/pnas.0508476103. Epub 2006 Feb 21. Proc Natl Acad Sci U S A. 2006. PMID: 16492744 Free PMC article.
• Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.

  Xiong S, Van Pelt CS, Elizondo-Fraire AC, Liu G, Lozano G. Xiong S, et al. Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3226-31. doi: 10.1073/pnas.0508500103. Epub 2006 Feb 21. Proc Natl Acad Sci U S A. 2006. PMID: 16492743 Free PMC article.
• Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.

  Toledo F, Wahl GM. Toledo F, et al. Nat Rev Cancer. 2006 Dec;6(12):909-23. doi: 10.1038/nrc2012. Nat Rev Cancer. 2006. PMID: 17128209 Review.
• A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.

  Toledo F, Krummel KA, Lee CJ, Liu CW, Rodewald LW, Tang M, Wahl GM. Toledo F, et al. Cancer Cell. 2006 Apr;9(4):273-85. doi: 10.1016/j.ccr.2006.03.014. Cancer Cell. 2006. PMID: 16616333
• Mouse models of Mdm2 and Mdm4 and their clinical implications.

  Xiong S. Xiong S. Chin J Cancer. 2013 Jul;32(7):371-5. doi: 10.5732/cjc.012.10286. Epub 2013 Jan 18. Chin J Cancer. 2013. PMID: 23327795 Free PMC article. Review.